Anti-Müllerian Hormone and Embryo Aneuploidy

Clinica de la Mujer Medicina Reproductiva, Chile300 enrolled

Overview

The goal of this observational study is to determine is there an association between the rates of aneuploidy and the different ranges of serum Antimullerian hormone (AMH) levels. Retrospective, single-centre study of patients undergoing IVF and preimplantation genetic testing with aneuploidy at the blastocyst stage between January 2018 and December 2022.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Infertility Aneuploidy

Interventions

preimplantation genetic test for aneuploidies (PGT-a)OTHER

preimplantation genetic test for embryo aneuploidies after IVF

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * All started cycles planned to be followed by preimplantation genetic testing for aneuploidies (PGT-A). PGT-A is proposed to the couples for the following reasons: advanced maternal age, recurrent miscarriage, repeated implantation failure or severe male infertility factor; it is also offered to all patients with a good prognosis who desired information regarding the ploidy status of their embryos. Exclusion Criteria: * Data from oocyte donation cycles

Locations (1)

Clinica de la Mujer Medicina Reproductiva

Viña del Mar, Región de Valparaíso, Chile

Outcomes

Primary Outcomes

Aneuplody rate

Time frame: 4 years

Secondary Outcomes

Clinical pregnancy rate

Time frame: 4 years

Miscarriage rate

Time frame: 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.